Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New supplement tested for cough and phlegm relief

NCT ID NCT05544942

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a supplement called GCWB1001 can help adults with mild breathing symptoms like cough, phlegm, and chest tightness. 120 people took either the supplement or a placebo for 12 weeks. The goal was to see if symptoms improved and if it was safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Aug 2022

Finished

Aug 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 69 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. At the time of screening, 19 or 70 years 2. Those who have two or more symptoms of cough, sputum, lake striking or chest stuffy for more than one month, and BCSS at 3 or more 3. Those with FEV 1 /FVC 70 or higher 4. Those who agreed to participation in this human application test before the beginning of the human test and signed in the Informed Consent Form Exclusion Criteria: 1. Severe cardiovascular, immune system, gastrointestinal and biliary meters, kidney and urinary systems, Those who are currently treated with neurological system, musculoskeletal system, mental, infectious diseases and malignant tumors 2. Those who have clinically significant respiratory diseases findings as a result of chest X-ray shooting 3. Those who have been diagnosed with chronic obstructive pulmonary disease (COPD) or asthma 4. Chronic bronchitis (BCSS 9 or more points or more Those who have continuous cough, sputum symptoms for more than 3 months) 5. A person who has a respiratory symptom due to virus or bacteria within 4 weeks of visit (Influenza, Corona Virus infection 19, pneumonia, acute infection, etc.) However, if the corona virus infection 19 has worsened or new symptoms of respiratory symptoms occur (However, if there are no additional respiratory symptoms caused by corona-19 infections, you can participate after 4 weeks after isolation. In the case of additional respiratory symptoms, the symptoms improve and can be participated if they have been restored to the time of recovery so that there is no difference compared to before infection.) 6. Those who take drugs for the purpose of taking immunosuppressive agents, or for the purpose of regulating Jinhae expectoration within 4 weeks of visit. 7. Those who take health functional foods related to improvement of respiratory health within 2 weeks of visit 1 8. Those who administered antibiotics within 2 weeks of visiting 1 9. Probiotics and those who consistently consume lactic acid bacteria products (4 or more times a week) within 2 weeks 10. Those who are less than 6 months after smokers or smoking cessation 11. Less than 4 weeks of visit, a person who falls under alcohol with an average of 30 g (210 shares) per day (210 weeks), an average of 20 g or more (140 shares) per day (140 shares) 12. Those who are more than twice the summit of Creatinine. 13. AST (G OT) or ALT (GPT) is three times more than the normal upper limit of the embodiment 14. Inconsidable high blood pressure patients systolic blood pressure 160 mmHg or higher or relaxation blood pressure 100 mmHg or higher, test target 10 minutes stabilization 15. Ungodined diabetic patient empathy 180 mg/dL or more 16. Those who are pregnant or have a planning plan for lactation or this human application period 17. Those who have been administered to include other arbitral clinical trial applications within 3 months of visitor and have received food for adoption of drugs for clinical trials. Those who plan to participate 18. Those who are sensitive or allergic to food ingredients for this human application 19. Those who judge that the tester is inadequate for other reasons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic bronchitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic bronchitis Signs and Symptoms, Respiratory

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chungbuk national university hospital

    Taebuk, South Korea

  • HALLYM UNIV. Chuncheon MEDICAL CENTER

    Chuncheon, South Korea

  • Hallym Univ. Medical Center

    Gyeonggi-do, South Korea

  • Hanyang University Seoul Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.